相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Detecting Fibroblast Activation Proteins in Lymphoma Using 68Ga-FAPI PET/CT
Xiao Jin et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET
Federico Simonetta et al.
CLINICAL CANCER RESEARCH (2021)
Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.
Paul Blanc-Durand et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA
Steven Le Gouill et al.
BLOOD (2021)
Prognostic Value of Baseline Radiomic Features of 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma
Kun-Han Lue et al.
DIAGNOSTICS (2021)
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
Johannes Duell et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
18F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study
Ryogo Minamimoto et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy
Laetitia Vercellino et al.
FRONTIERS IN ONCOLOGY (2021)
Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring
Fuqiang Shao et al.
THERANOSTICS (2021)
CXCR4 PET imaging of mantle cell lymphoma using [68Ga]Pentixafor: comparison with [18F]FDG-PET
Marius E. Mayerhoefer et al.
THERANOSTICS (2021)
Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project
Clement Bailly et al.
HAEMATOLOGICA (2020)
18F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome
Anne-Segolene Cottereau et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial
Christine Schmitz et al.
EUROPEAN JOURNAL OF CANCER (2020)
ImmunoPET: Concept, Design, and Applications
Weijun Wei et al.
CHEMICAL REVIEWS (2020)
Baseline 18F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy
Nicolas Aide et al.
EUROPEAN RADIOLOGY (2020)
Tumor Segmentation and Feature Extraction from Whole-Body FDG-PET/CT Using Cascaded 2D and 3D Convolutional Neural Networks
Skander Jemaa et al.
JOURNAL OF DIGITAL IMAGING (2020)
The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping
Alex Zwanenburg et al.
RADIOLOGY (2020)
[18F]FDG-PET/CT Radiomics for Prediction of Bone Marrow Involvement in Mantle Cell Lymphoma: A Retrospective Study in 97 Patients
Marius E. Mayerhoefer et al.
CANCERS (2020)
Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG
Qingqing Pan et al.
EJNMMI RESEARCH (2020)
Molecular imaging in lymphoma beyond 18F-FDG-PET: understanding the biology and its implications for diagnostics and therapy
Xaver U Kahle et al.
Lancet Haematology (2020)
ImmunoPET in Multiple Myeloma-What? So What? Now What?
Clement Bailly et al.
CANCERS (2020)
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
Laetitia Vercellino et al.
BLOOD ADVANCES (2020)
Metabolic Tumor Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma
Jasmin Mettler et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Side Effects of CXC-Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation
Sabine Maurer et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Tumor Identification of Less Aggressive or Indolent Lymphoma With Whole-Body 11C-Acetate PET/CT
Junichi Tsuchiya et al.
CLINICAL NUCLEAR MEDICINE (2019)
Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study
Sally F. Barrington et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
68Ga-Pentixafor PET/CT for Imaging of Chemokine Receptor 4 Expression in Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT
Yaping Luo et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Diagnosis and management of follicular lymphoma: A comprehensive review
Reyad Dada
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma
Marius E. Mayerhoefer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome
Julia Richter et al.
BLOOD CANCER JOURNAL (2019)
The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma: An Individual Patient Data Meta-Analysis By the Petra Consortium
Jakoba J. Eertink et al.
BLOOD (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study
Rene-Olivier Casasnovas et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
[18F]-Fludarabine for Hematological Malignancies
Louisa Barre et al.
FRONTIERS IN MEDICINE (2019)
Interest of FDG-PET in the Management of Mantle Cell Lymphoma
Clement Bailly et al.
FRONTIERS IN MEDICINE (2019)
Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
Anne-Segolene Cottereau et al.
BLOOD (2018)
Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma
Pierre Decazes et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma
Hajira Ilyas et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma
Mathieu Nessim Toledano et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial
Andrea Gallamini et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
18F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients
Sylvain Chantepie et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Response rate to lenalidomide plus rituximab (R-2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.
David Andorsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
18F-Choline and 18F-FDG PET/CT in a Patient With Diffuse Large B-Cell Lymphoma and Recurrent Prostate Cancer
Nicolas De Leiris et al.
CLINICAL NUCLEAR MEDICINE (2018)
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
Judith Trotman et al.
LANCET ONCOLOGY (2018)
Zr-89-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
Frederike Bensch et al.
NATURE MEDICINE (2018)
Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation
Mani Akhtari et al.
BLOOD (2018)
Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma
Marie-Helene Delfau-Larue et al.
BLOOD ADVANCES (2018)
Comparison of 11C-Methionine and 18F-FDG PET/CT for Staging and Follow-up of Pediatric Lymphoma
Sue C. Kaste et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma
Anne-Segolene Cottereau et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
Marc P. E. Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group
Peter Borchmann et al.
LANCET ONCOLOGY (2017)
Association between textural and morphological tumor indices on baseline PET-CT and early metabolic response on interim PET-CT in bulky malignant lymphomas
Faycal Ben Bouallegue et al.
MEDICAL PHYSICS (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
Yvonne W. S. Jauw et al.
PLOS ONE (2017)
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
Alison J. Moskowitz et al.
BLOOD (2017)
Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report
Mira Tout et al.
BLOOD (2017)
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy
Bruce D. Cheson et al.
BLOOD (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma
Anne-Segolene Cottereau et al.
CLINICAL CANCER RESEARCH (2016)
ImmunoPET to help stratify patients for targeted therapies and to improve drug development
Francoise Kraeber-Bodere et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Comparative Analysis between [18F]Fludarabine-PET and [18F]FDG-PET in a Murine Model of Inflammation
Narinee Hovhannisyan et al.
MOLECULAR PHARMACEUTICS (2016)
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma
Peter Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring
Ryogo Minamimoto et al.
RADIOLOGY (2016)
Radiomics: Images Are More than Pictures, They Are Data
Robert J. Gillies et al.
RADIOLOGY (2016)
Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin lymphoma (HL) enrolled in the AHL2011 LYSA trial.
Rene-Olivier Casasnovas et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas - Interim PET-Based Outcome Prediction and Treatment Changes in Patients with B Cell Lymphomas Participating in the PETAL Trial
Ulrich Duehrsen et al.
BLOOD (2016)
Incidental Detection of a Hodgkin Lymphoma on 18F-Choline PET/CT and Comparison With 18F-FDG in a Patient With Prostate Cancer
Aurore Goineau et al.
CLINICAL NUCLEAR MEDICINE (2015)
Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab
Kristoff Muylle et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
Christoph Mamot et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study
Mark Roschewski et al.
LANCET ONCOLOGY (2015)
Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin's Lymphoma
John Radford et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Evaluation of the specificity of [18F]fludarabine PET/CT in a xenograft model of follicular lymphoma: comparison with [18F]FDG and impact of rituximab therapy
Narinee Hovhannisyan et al.
EJNMMI RESEARCH (2015)
Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F] FDG PET to Predict Survival in Hodgkin Lymphoma
Salim Kanoun et al.
PLOS ONE (2015)
Predictive Power of FDG-PET Parameters at Diagnosis and after Induction in Patients with Mantle Cell Lymphoma, Interim Results from the LyMa-PET Project, Conducted on Behalf of the Lysa Group
Caroline Bodet-Milin et al.
BLOOD (2015)
State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PET
Thomas Carlier et al.
FRONTIERS IN MEDICINE (2015)
Incidental Diagnosis of Diffuse Large B-Cell Lymphoma by 11C-Choline PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer
J. R. Garcia Garzon et al.
CLINICAL NUCLEAR MEDICINE (2014)
A Pilot Study of the Value of 18F-Fluoro-Deoxy-Thymidine PET/CT in Predicting Viable Lymphoma in Residual 18F-FDG Avid Masses After Completion of Therapy
Esther Mena et al.
CLINICAL NUCLEAR MEDICINE (2014)
FDG PET/CT methodology for evaluation of treatment response in lymphoma: from graded visual analysis and semiquantitative SUVmax to global disease burden assessment
Sandip Basu et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma
Myriam Sasanelli et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale
Andrea Gallamini et al.
HAEMATOLOGICA (2014)
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Sally F. Barrington et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Omitting Radiotherapy in Early Positron Emission Tomography-Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial
John M. M. Raemaekers et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Early Determination of Prognosis by Interim 3′-Deoxy-3′-18F-Fluorothymidine PET in Patients with Non-Hodgkin Lymphoma
Hyewon Lee et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Interim 18F-FDG PET SUVmax Reduction Is Superior to Visual Analysis in Predicting Outcome Early in Hodgkin Lymphoma Patients
Cedric Rossi et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies
Judith Trotman et al.
LANCET HAEMATOLOGY (2014)
Radiomics in PET: principles and applications
Gary J. R. Cook et al.
CLINICAL AND TRANSLATIONAL IMAGING (2014)
PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement
Anjum Bashir Khan et al.
BLOOD (2013)
[F-18]FLT is superior to [F-18]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner
Nicolas Graf et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax
Emmanuel Itti et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Gonadal Function and Fertility in Survivors After Hodgkin Lymphoma Treatment Within the German Hodgkin Study Group HD13 to HD15 Trials
Karolin Behringer et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers
Alberto Biggi et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP
Patrizia Pregno et al.
BLOOD (2012)
Early interim F-18-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients
Pier Luigi Zinzani et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Routine Bone Marrow Biopsy Has Little or No Therapeutic Consequence for Positron Emission Tomography/Computed Tomography-Staged Treatment-Naive Patients With Hodgkin Lymphoma
Tarec Christoffer El-Galaly et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma
Rene -Olivier Casasnovas et al.
BLOOD (2011)
Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses
Andrea Gallamini et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Role of Functional Imaging in the Management of Lymphoma
Bruce D. Cheson
JOURNAL OF CLINICAL ONCOLOGY (2011)
Predictive Value of Initial 18F-FLT Uptake in Patients with Aggressive Non-Hodgkin Lymphoma Receiving R-CHOP Treatment
Ken Herrmann et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned
Simonetta Viviani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group
Caroline Bodet-Milin et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Role of [18F] Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma
Pier Luigi Zinzani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study
Andreas Engert et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Report on the First International Workshop on interim-PET scan in lymphoma
Michel Meignan et al.
LEUKEMIA & LYMPHOMA (2009)
Impact of [18F] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma
Andrew Wirth et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma
Fabio M. Iwamoto et al.
CANCER (2007)
Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT
Andreas K. Buck et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
The international harmonization project for response criteria in lymphoma clinical trials
Bruce D. Cheson
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2007)
Early interim 2-[18F]Fluoro-2-Deoxy-D-Glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma:: A report from a joint Italian-Danish study
Andrea Gallamini et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma
Malik E. Juweid et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population
M. Liedtke et al.
ANNALS OF ONCOLOGY (2006)
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
M Hutchings et al.
BLOOD (2006)
Image-aided estimate of tumor burden in Hodgkin's disease:: Evidence of its primary prognostic importance
PG Gobbi et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)